Clinical trial
HLA-B*5701 And Hypersensitivity To Abacavir
NCT00373945 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00373945 |
|---|---|
| Title | HLA-B*5701 And Hypersensitivity To Abacavir |
| Official title | A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | Observational Study |
| Enrollment | 280 |
| Start date | Aug 1, 2006 |
| Completion | Aug 1, 2007 |
| First posted | Sep 8, 2006 |
| Last update posted | May 18, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: